|
|
Article: Dainippon Sumitomo Pharma to Acquire Sepracor for U.S. $23.00 Per Share in an All-Cash Tender Offer Valued at Approximately U.S. $2.6 Billion.
- Article from:
- Biotech Week
- Article date:
- September 16, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Dainippon Sumitomo Pharma Co., Ltd. ("DSP", TSE: 4506) and Sepracor Inc. ("Sepracor", Nasdaq: SEPR) announced that they have entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately $2.6 billion through a cash tender offer of $23.00 per share, followed by a merger to acquire all remaining outstanding Sepracor shares at the same price paid in the tender offer. The tender offer price represents a 48.0% premium to Sepracor's average stock price over the last six month period ending on September 1, and a 27.6% premium over the closing price of Sepracor's common stock on September 1, 2009. The transaction was unanimously approved by the ...
Related newspaper, magazine, and journal articles:
|
|
Article: Sepracor Announces Additional Equity Investment in ACADIA.
Business Wire;
January 17, 2006 ;
700+ words
... ... disorders." ACADIA and Sepracor established their ... treatment of central nervous system (CNS) disorders ... medical needs. Sepracor's drug development ... respiratory and central nervous system disorders. Sepracor's corporate headquarters ...
|
|